Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia

Laryngoscope

Volumn 119, Issue 10, 2009, Pages 2004-2007

  Vasconcelos, Silvio ^a   Birkent, Hakan ^b   Sardesai, Maya G ^c   Merati, Albert L ^c   Hillel, Allen D ^c  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Age gender dose; Botulinum toxin; Duration of response; Laryngeal dystonia; Spasmodic dysphonia

Indexed keywords

BOTULINUM TOXIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DYSTONIA; FEMALE; HUMAN; LARYNX DISORDER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; VOICE DISORDERS; YOUNG ADULT;

EID: 70349964533     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20564     Document Type: Article

References (11)

1. Blitzer A, Brin MF, Fahn S, Lovelace RE. Clinical and laboratory characteristics of focal laryngeal dystonia: study of 110 cases. Laryngoscope 1988;98:636-640.
2. Klotz DA, Maronian NC, Waugh PF, Shahinfar A, Robinson L, Hillel AD. Findings of multiple muscle involvement in a study of 214 patients with laryngeal dystonia using fine-wire electromyography. Ann Otol Rhinol Laryngol 2004;113:602-612.
3. Blitzer A, Brin MF, Fahn S, Lovelace RE. Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia). Laryngoscope 1988;98: 193-197.
4. Zwirner P, Murry T, Swenson M, Woodson GE. Effects of botulinum toxin therapy in patients with adductor spasmodic dysphonia: acoustic, aerodynamic, and videoendoscopic findings. Laryngoscope 1992;102:400-406.
5. Langeveld TP, van Rossum M, Houtman EH, Zwinderman AH, Briaire JJ, Baatenburg de Jong RJ. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment. Ann Otol Rhinol Laryngol 2001;110:627-634.
6. Hogikyan ND, Wodchis WP, Spak C, Kileny PR. Longitudinal effects of botulinum toxin injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia. J Voice 2001;15:576-586.
7. Rubin AD, Wodchis WP, Spak C, Kileny PR, Hogikyan ND. Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II. Arch Otolaryngol Head Neck Surg 2004;130:415-420.
8. Mau T, Courey MS. Influence of gender and injection site on vocal fold augmentation. Influence of gender and injection site on vocal fold augmentation. Otolaryngol Head Neck Surg 2008;138:221-225.
9. Cannito MP, Kahane JC, Chorna L. Vocal aging and adductor spasmodic dysphonia: response to botulinum toxin injection. Clin Interv Aging 2008;3:131-151.
10. Birkent H, Maronian N, Waugh P, Merati AL, Perkel D, Hillel AD. Dosage changes in patients with long-term botulinum toxin use for laryngeal dystonia. Otolaryngol Head Neck Surg 2009;140:43-47.
11. Connor NP, Suzuki T, Lee K, et al. Neuromuscular junction changes in rat thyroarytenoid muscle. Ann Otol Rhinol Laryngol 2002;111(7 pt 1):579-586.